A phase 2a trial of brepocitinib for cicatricial alopecia

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Cicatricial alopecias are progressive scarring hair loss conditions with poorly understood molecular drivers.
• Th1/IFNγ signaling and Janus kinase (JAK) dysregulation are implicated in these conditions.
• Brepocitinib, a Tyrosine kinase 2/Janus kinase 1 inhibitor, was investigated for its therapeutic potential.

Purpose of the Study:

• To evaluate the efficacy and safety of brepocitinib in patients with cicatricial alopecias.
• To assess the drug's impact on key molecular markers of inflammation and fibrosis.
• To determine the clinical benefit of brepocitinib in improving hair loss severity.

Main Methods:

• A 52-week, randomized, placebo-controlled phase 2a trial was conducted.
• Adult patients with lichen planopilaris, frontal fibrosing alopecia, or central centrifugal cicatricial alopecia received brepocitinib (45 mg daily) or placebo for 24 weeks.
• Lesional scalp biopsies were analyzed for C-C motif chemokine ligand (CCL5) and fibrosis markers; clinical severity scores were also assessed.

Main Results:

• Brepocitinib treatment led to significant downregulation of lesional CCL5 expression at 24 weeks (P = .004).
• A subset of fibrosis markers showed a trending upregulation in the placebo group.
• Brepocitinib was well tolerated and associated with improvements in clinical severity scores.

Conclusions:

• Brepocitinib met its coprimary endpoints by significantly reducing CCL5 expression and demonstrating a favorable safety profile at 24 weeks.
• The drug effectively reduces inflammatory biomarker expression and improves clinical outcomes in patients with scarring alopecia.
• Further investigation into brepocitinib's long-term efficacy and safety is warranted.